Skip to content

Randomized Trial Evaluating the Effectiveness of the General Practitioner Involvement in Cancer Screening Invitations

Randomized Trial Evaluating the Effectiveness of a Targeted Communication With the General Practitioner Involvement in Cancer Screening Invitation Letters

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02367001
Acronym
GPs
Enrollment
53978
Registered
2015-02-20
Start date
2014-02-28
Completion date
2015-09-30
Last updated
2015-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Cervical Cancer, Colorectal Cancer

Keywords

general practitioner, screening, participation, organized screening

Brief summary

Our goal is to evaluate, in France, the effectiveness (in terms of participation) of the general practitioner involvement (signature) and a more personalized communication in invitation letters to organized screening of breast, colorectal and cervical cancers. The hypothesis on which this project is based is that communication is probably more effective if the receiver feels personally targeted by invitation letters (Dear Martin, I am writing ...) and if he knows the issuer (his general practitioner rather an unknown person).

Interventions

OTHERNormal invitation

No modification and signed by the coordinating doctor as usual

OTHERrevised invitation signed by the coordinating doctor

Invitation with revised text and layout and signed by the coordinating doctor as usual

OTHERRevised invitation signed by the attending physician

signature typed or typed + handwritten

Sponsors

University Hospital, Tours
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
25 Years to 74 Years
Healthy volunteers
No

Inclusion criteria

* Living in Indre-et-Loire (french territorial division 37) * Be affiliated to the following three health insurance companies: CPAM (Caisse Primaire d'Assurance Maladie), MSA (Mutualité Sociale Agricole), or RSI (Régime social des Indépendants) * Having declared (to health insurance company) an attending physician who has given its written consent to participate in the study * Present no exclusion criterion to cancer screening ( for each one) * Be old from 50 to 74 years (breast and colorectal cancer) or from 25 to 65 years (cervical cancer)

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the effect on the participation (of the population) in cancer screening of an intervention involving the general practitioner (integration of signature) in the invitation letters9 or 12 months after the invitation lettersThe participation / non participation will be measured for each cancer screening (breast, colorectal and cervical) : * 9 months after the invitation letters for breast and colorectal cancers * 12 months after the invitation letters for cervical cancer The participation rate is defined as the number of people having participated, divided by the total number of people in the group or subgroup considered. Analysis by comparing the participation rates between groups (Group 1, Group 2 and Group 3) and sub-groups will be done.

Secondary

MeasureTime frame
Evaluate the effectiveness on the participation (of the population) of the use of a simplified and more focused communication in the invitation letters : comparison of the participation rates in arm 1 (normal invitation) and arm 2 (revised invitation)9 or 12 months after the invitation letters
Evaluate the effectiveness on the participation (of the population) of the two types of general practitioner signature (typed versus typed + handwritten) by comparing the participation rates between two sub-groups in the arm 3.9 or 12 months after the invitation letters
Cost-effectiveness of different strategies for each cancer screening (breast, colorectal and cervical) as measured by cost effectiveness ratio (total costs in Euros divided by total screened people)9 or 12 months after the invitation letters

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026